Technical Analysis for AGRX - Agile Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.37 | 0.60% | 0.00 |
AGRX closed up 0.6 percent on Thursday, April 18, 2024, on 2 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
20 DMA Resistance | Bearish | 0.60% | |
Outside Day | Range Expansion | 0.60% | |
Wide Bands | Range Expansion | 0.60% | |
Fell Below 20 DMA | Bearish | -4.05% | |
NR7 | Range Contraction | -4.05% | |
Narrow Range Bar | Range Contraction | -4.05% |
Alert | Time |
---|---|
Possible NR7 | about 4 hours ago |
Possible Inside Day | about 4 hours ago |
Up 3% | about 6 hours ago |
Up 2% | about 6 hours ago |
Up 1% | about 7 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Clinical Development Alcohol Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Clinical Development Alcohol Organic Compounds Estrogen Transdermal Estranes Hormonal Contraception Medroxyprogesterone Acetate
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.97 |
52 Week Low | 0.2 |
Average Volume | 907,017 |
200-Day Moving Average | 1.76 |
50-Day Moving Average | 0.69 |
20-Day Moving Average | 0.39 |
10-Day Moving Average | 0.39 |
Average True Range | 0.10 |
RSI (14) | 42.53 |
ADX | 24.49 |
+DI | 25.48 |
-DI | 18.19 |
Chandelier Exit (Long, 3 ATRs) | 0.38 |
Chandelier Exit (Short, 3 ATRs) | 0.49 |
Upper Bollinger Bands | 0.60 |
Lower Bollinger Band | 0.18 |
Percent B (%b) | 0.45 |
BandWidth | 106.55 |
MACD Line | -0.08 |
MACD Signal Line | -0.11 |
MACD Histogram | 0.0303 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.40 | ||||
Resistance 3 (R3) | 0.40 | 0.39 | 0.39 | ||
Resistance 2 (R2) | 0.39 | 0.39 | 0.39 | 0.39 | |
Resistance 1 (R1) | 0.38 | 0.38 | 0.39 | 0.38 | 0.39 |
Pivot Point | 0.37 | 0.37 | 0.38 | 0.37 | 0.37 |
Support 1 (S1) | 0.36 | 0.37 | 0.37 | 0.36 | 0.35 |
Support 2 (S2) | 0.35 | 0.36 | 0.35 | 0.35 | |
Support 3 (S3) | 0.34 | 0.35 | 0.35 | ||
Support 4 (S4) | 0.34 |